Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Investor Presentation (April 2022)
26 slides from Matinas Biopharma's investor presentation, Apr 13, 2022
Slide 1: Corporate Presentation April 2022
MATINA BIOPHARMA \ Corporate ea April 2022
Slide 2: Forward-Looking Statement
Looking Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, cash flow and other statements t
Slide 3: LNCs Simplify Intracellular Delivery of Nucleic Acids
LNCs Simplify Intracellular Delivery of Nucleic Acids ; Description Benefit M h t trophil . a papal TARGET acrop ages/monocytes, neutrophils, Wide variety of extrahepatic rates ‘ACTIVATED” CELLS dendritic cells targets s Infected/injured cells, tumor cells 8 Non-immunogenic platform IMPROVED Enables
Slide 4: Matinas Pipeline and Discovery Programs: Internal and Collaborative
Matinas Pipeline and Discovery Programs: Internal and Collaborative MAT2203 MATINAS ___LNc-amphotericin B | Cohort 4 Commenced January 2022 » BIOPHARMA (oral) MAT2501 228 éysticrisrosis_ LNC-Amikacin (oral) FOUNDATION™ MATINAS BIOPHARMA Phase1 SAD Study results mid-2022 LNC-Remdesivir In vitro and i
Slide 5: Exclusive Research Collaboration with BioNTech
Exclusive Research Collaboration with BioNTech MATINAS 3lO —C rf BIOPHARMA Exclusive collaboration between Matinas and BioNTech focused on mRNA and certain other nucleic acids BioNTech’s mRNA vaccine development expertise combined with Matinas’ LNC delivery platform Builds on Matinas’ extensive prio
Slide 6: Exclusive Research Collaboration with BioNTech Builds on Previous Vaccine Results
Exclusive Research Collaboration with BioNTech Builds on Previous Vaccine Results EMICAeY Bie viously demonstrated LNCs Provide Differentiation w/LNCs (in-vivo) Y Successful oral immunization Y Can be administered SQ, IM, via VY Substantial increases in antibody titers inhalation, and orally V Enhan
Slide 7: Lipid Nanocrystal (LNC) Platform
Lipid Nanocrystal (LNC) Platform Targeted, Well-Tolerated Intracellular Delivery —
Slide 8: LNCs Work Because of PS, Which Enables Intracellular Delivery Via Two Biological Pathways
LNCs Work Because of PS, Which Enables Intracellular Delivery Via Two Biological Pathways PS on the outer layer is an “eat-me” signal PS on the outer cell membrane is also enabling phagocytosis a precursor for cell to cell fusion = Myoblast Egg and Sperm Infection - Se & Injury == + Inflammation Se
Slide 9: Intracellular Uptake Via Phagocytosis or Fusion Enables Targeting to Phagocytes and Activated Cells
Intracellular Uptake Via Phagocytosis an r Fusion Enables Targeting to Phagocytes and “Activated” Cells Phagocytosis Initiated by binding of PS to PS receptors Initiated by expression of PS on the surface of cells Fusion \\ Macrophage Macrophages readily engulf LNCs and their cargo into vesicles (en
Slide 10: LNCs Provide A Differentiated Alternative to NP and AAV Delivery of Nucleic Acids
LNCs Provide A Differentiated Alternative to NP and AAV Delivery of Nucleic Acids Structure Targeting Payload Safety Stability 10 = lonizable lipid complexing with mRNA * Non-aqueous interior 26 nM Capsid housing Natural components Non-aqueous bilayer Avid uptake by RES, liver, spleen limits availab
Slide 11: Multiple Potential Future Directions For LNC Platform
Multiple Potential Future Directions For LNC Platform Past Current Future . Antivirals Infection Intracellular delivery of Vaccines 2 ‘ Immune system nucleic acids Immune tolerance Oral Inflammation formulations of anti- Oncolo infectives By A Diseases of . F MAT. Monogenetic rare diseases phagocyte
Slide 12: MAT2203 Oral Amphotericin B
MAT2203 Oral Amphotericin B MATINAS BIOPHARMA
Slide 13: Invasive Fungal Infections Represent an Urgent Growing Global Need
Invasive Fungal Infections Represent an Urgent Growing Global Need Invasive fungal infections are an urgent and largely overlooked global problem due to increasing use of immunosuppressive therapies, and growing resistance to current anti-fungal therapies due to lack of recent innovation. Global Inv
Slide 14: Oral amphotericin B formulation utilizing LNCs
= Oral amphotericin B formulation utilizing LNCs = Proprietary formulation with robust intellectual property protection MAT2203 pristary Property P = Potential to expand beyond treatment of CM to treatment of other invasive infections and prophylaxis = Program supported by the National Institutes of
Slide 15: EnACT Study Design
EnACT Study Design Induction (2 weeks) Vv Cohort1 MW (n=10) 5 days Y¥ Cohort 2 (VE (n=40) 2 days v Cohort 3 IV AMB (n=10) days (overlap 1 day) Adjunctive Rx | SFC ity (EFA) > 0.20 Early Consolidation (4 weeks) (all cohorts) Fluconazole §}_——————_> MAT2203 TREATMENT REGIMENS: Cohort 1 * Induction: 2.
Slide 16: EnACT Cohort 2 Met Primary Endpoints
EnACT Cohort 2 Met Primary Endpoints EnACT Cohort 2 Endpoints EnACT Cohort 2 Results = Primary Endpoint: Early Fungicidal Activity (EFA) log,, CFU/mL/day at D 1430 a sin GRRL aay at Day » V EFA for MAT2203 was 0.42 (95% Cl 0.29 to 0.55), exceeding the . . primary endpoint threshold = EFA > 0.20 - as
Slide 17: MAT2203 Updates and Upcoming Milestones
MAT2203 Updates and Upcoming Milestones EnACT Updates FDA Feedback and Next Steps * Additional analyses of Cohort 2 Data Demonstrate: ¢ End-of-Phase 2 Meeting held December 2021 (1) “Early Survival” at Day 30 ¢ No questions raised on efficacy, safety or tolerability (a) 98% for patients receiving MA
Slide 18: EnACT Cohort Results Provide Important Validation of LNC Platform Capabilities
EnACT Cohort 2 Results Provide Important Validation of LNC Platform Capabilities ul to MAT2203 Extendable to LNC Platform = Adding oral to IV delivery " True targeted intracellular delivery = Reducing treatment-limiting toxicity « Repeated administration without . signs of immunogenicity = Able to d
Slide 19: MAT2501 Oral Amikacin
MAT2501 Oral Amikacin MATINAS BIOPHARMA
Slide 20: MAT2501: A Better Amikacin
1: A Better Amikacin = Oral, LNC formulation of the broad-spectrum antibiotic Amikacin = Initial indication in treatment of non-tuberculous mycobacterial (NTM) infections sueureeci = QIDP and Orphan Designations potentially provide 12+ years of exclusivity upon approval = Proprietary formulation wit
Slide 21: NTM Program Overview
: NTM Prog Overview Non-Tuberculous Mycobacterial Disease NTM organisms, widely present in the environment, are a frequent cause of challenging pulmonary infections, especially in patients with pre-existing inflammatory lung diseases such as cystic fibrosis Approximately 40-60% of patients have infe
Slide 22: Driving Opportunities for Value-Added Partnerships Built around the LNC Platform
Driving Opportunities for Value-Added Partnerships Built around the LNC Platform Genentech = In 2019, we entered a collaboration a Genentech/Roche to evaluate LNC delivery of up to A Member of the Roche Group three molecules, including antisense oligonucleotides. a = In November 2020, announced $3.7
Slide 23: Expanding LNC Intellectual Property Portfolio
Expanding LNC Intellectual Property Portfolio 20 Patents Issued Within Last 5 Years 30+ PENDING PATENT APPLICATIONS ACROSS PLATFORM COULD, EXTEND TO 2040 Additional IP to be developed as clinical development plan progresses. Regulatory Exclusivity MAT2203 and MAT2501 both have QIDP and Orphan Design
Slide 24: Executive Officers and Board of Directors
Executive Officers and Board of Directors EXECUTIVE OFFICERS Jerome D. Jabbour Co-Founder, Chief Executive Officer Thomas Hoover, MBA Chief Business Officer James J. Ferguson III, M.D., FACC, FAHA Chief Medical Officer Theresa Matkovits, Ph.D. Chief Development Officer Keith A. Kucinski, CPA, MBA Ch
Slide 25: Summary and 2022 Milestones & Catalysts
Summary and 2022 Milestones & Catalysts 1H 2022 Milestones & Catalysts 2H 2022 Milestones & Catalysts FDA Feedback on Cohort 5 of ry Interim Topline Data from Cohort EnACT 4 of EnACT MAT2203 Initiate preclinical studies of | Data from MAT2203 preclinical MAT2203 in C. auris and studies in C. auris a
Slide 26: Matinas BioPharma Corporate Presentation April 2022
MATINA BIOPHARMA \ Corporate ea April 2022
Matinas BioPharma Holdings — Investor Presentation (April 2022) on 6ix